Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Infect Dis. 2023 Dec 20;228(12):1758-1765. doi: 10.1093/infdis/jiad211.
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed an unpreceded threat to the management of other pandemics such as human immunodeficiency virus-1 (HIV-1) in the United States. The full impact of the SARS-CoV-2 pandemic on the HIV-1 pandemic needs to be evaluated.
All individuals with newly reported HIV-1 diagnoses from NC State Laboratory of Public Health were enrolled in this prospective observational study, 2018-2021. We used a sequencing-based recency assay to identify recent HIV-1 infections and to determine the days postinfection (DPI) for each person at the time of diagnosis.
Sequencing used diagnostic serum samples from 814 individuals with new HIV-1 diagnoses spanning this 4-year period. Characteristics of individuals diagnosed in 2020 differed from those in other years. People of color diagnosed in 2021 were on average 6 months delayed in their diagnosis compared to those diagnosed in 2020. There was a trend that genetic networks were more known for individuals diagnosed in 2021. We observed no major integrase resistance mutations over the course of the study.
SARS-CoV-2 pandemic may contribute to the spread of HIV-1. Public health resources need to focus on restoring HIV-1 testing and interrupting active, ongoing, transmission.
持续的严重急性呼吸系统综合征冠状病毒 2 (SARS-CoV-2)大流行对美国其他大流行(如人类免疫缺陷病毒 1 (HIV-1))的管理构成了前所未有的威胁。需要评估 SARS-CoV-2 大流行对 HIV-1 大流行的全面影响。
本前瞻性观察研究纳入了 2018 年至 2021 年期间在北卡罗来纳州公共卫生实验室新报告的 HIV-1 诊断的所有个体。我们使用基于测序的近期检测法来识别最近的 HIV-1 感染,并确定每个人在诊断时的感染后天数(DPI)。
该研究使用了来自 814 名新诊断 HIV-1 患者的诊断血清样本,时间跨度为 4 年。2020 年确诊患者的特征与其他年份不同。2021 年被诊断为有色人种的患者平均比 2020 年的患者延迟 6 个月进行诊断。趋势表明,2021 年确诊的患者,其基因网络更为人所知。在研究过程中,我们未观察到主要的整合酶耐药突变。
SARS-CoV-2 大流行可能会助长 HIV-1 的传播。公共卫生资源需要集中精力恢复 HIV-1 检测并中断正在进行的传播。